Skip to content

Evaluating the Effect of Silymarin on CAPD Patients

Evaluating the Antioxidative Effect of Silymarin on CAPD Patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2013110315256N1
Enrollment
60
Registered
2013-12-09
Start date
2013-09-23
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal failure, peritoneal dyalisis. Renal failure

Interventions

Intervention 1: Receiving silymarin drug 140mg every 8 hours for 2 month. Intervention 2: in control group we used similar tablet in shape , color to Silymarin drug, which is consisted of starch as pl
Treatment - Drugs
Placebo
Receiving silymarin drug 140mg every 8 hours for 2 month
in control group we used similar tablet in shape , color to Silymarin drug, which is consisted of starch as placebo and they should take each hours for 2 month.

Sponsors

Shiraz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criterion: patients undergo Peritoneal Dialysis and are on the follow up of nephrologist at Emam reza Clinic between 18-60 years old. Exclusion criteria:patients undergo Peritoneal Dialysis who had peritonitis in recent 2 month; hepatitis; or using other antioxidant, anti pregnancy, levothyroxin drugs and smoking.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Glutathione peroxidase antioxidant enzyme in RBC. Timepoint: 2 month (before and after drug). Method of measurement: serlogic blood test.;Antioxidant catalase enzyme. Timepoint: 2 month (before and after drug). Method of measurement: serlogic blood test.;Antioxidant isoprostane enzye F2a. Timepoint: 2 month (before and after drug). Method of measurement: serlogic blood test.;Antioxidant capacity FRAP. Timepoint: 2 month (before and after drug). Method of measurement: serlogic blood test.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSoraya Khajeh Rezae

Shiraz Universitty of Medical Sciences

khajerezae@sums.ac.ir+98 71 1627 6826

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026